ArticleCureus2025
The Preparation of Dentin Matrix-Polycaprolactone Drug Carrier Scaffold and Its Application in Promoting Bone Formation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective The bioactivity of natural plant extracts, such as Chinese herbal medicines, is often limited by their poor water solubility. Therefore, selecting an appropriate drug carrier is crucial for exerting the pharmacological effects of these medicines. This study aimed to fabricate a dentin matrix-polycaprolactone (DM-PCL) drug carrier scaffold and evaluate its effects on the proliferation and differentiation of osteoblasts, thereby providing experimental support for subsequent drug loading applications. Methodology The DM-PCL carrier scaffold was constructed using electrospinning technology, and its surface morphology was observed by scanning electron microscopy (SEM). Osteoblasts were cultured in vitro, and the osteogenic effects of the DM-PCL scaffold were compared with those of a pure PCL scaffold through CCK-8 cell proliferation assay, live/dead cell staining, alkaline phosphatase (ALP) activity assay, cytoskeleton staining, and analysis of Runx2 mRNA expression levels. Results CCK-8 assay and live/dead staining showed that the DM-PCL drug carrier scaffold significantly promoted osteoblast proliferation (p<0.05). ALP activity detection indicated that the scaffold also enhanced early osteogenic differentiation (p>0.05). Phalloidin staining revealed a higher number of cells in the DM-PCL group, with adequate cell spreading and slightly clearer intracellular network structure and actin arrangement compared to the PCL group. Conclusions Based on our findings, the DM-PCL drug carrier scaffold can promote the adhesion, proliferation, and differentiation of osteoblasts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.